Musil J, Hirsch V, Vondra V, Reisová M
Oddĕlení TRN FN Motol, Praha.
Vnitr Lek. 1998 Jul;44(7):415-7.
The authors compared in a prospective study the bronchodilatating and undesirable effects of combined inhalation treatment (phenoterol + ipratropium bromide) in the treatment of patients with exacerbation of chronic obstructive pulmonary disease, using different dosages. The patients were divided at random into two groups--group one inhaled berodual sol 3.5 ml/day (i.e. 1.75 mg phenoteroli + 0.875 mg ipratropii bromidium), the second group had a dose of double size. During the trial the authors monitored the peak expiration rate, the heart and respiration rate, blood gases and the subjective state of dyspnoea, using a 10 cm line. By comparison of bronchodilatating and undesirable effects they reached the conclusion that a daily dose of 3.5 ml berodual sol. is sufficiently effective. Increasing the daily dose to 7 ml did not produce a greater therapeutic effect nor increase the risk of undesirable effects.
作者在一项前瞻性研究中，比较了联合吸入治疗（非诺特罗+异丙托溴铵）以不同剂量治疗慢性阻塞性肺疾病加重期患者时的支气管扩张作用和不良影响。患者被随机分为两组，第一组每天吸入3.5毫升贝罗杜尔溶液（即1.75毫克非诺特罗+0.875毫克异丙托溴铵），第二组剂量加倍。在试验过程中，作者使用一条10厘米长的线监测呼气峰值流速、心率和呼吸频率、血气以及呼吸困难的主观状态。通过比较支气管扩张作用和不良影响，他们得出结论：每天3.5毫升贝罗杜尔溶液的剂量足够有效。将每日剂量增加到7毫升并没有产生更大的治疗效果，也没有增加不良影响的风险。
